Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
Recruiting · NCT06096974 · Registry updated 2025-04-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS | Advanced Solid Tumors | Recruiting | Phase 1 | 2025-04-09 | NCT06096974 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai YingLi Pharmaceutical Co. Ltd. | 5 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Huntsman Cancer Institute and Hospital, University of Utah | Salt Lake City | United States | 1 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| The Lindner Center for Research & Education at The Christ Hospital | Cincinnati | United States | 2 |